Share this page!

Matt Hall Profile picture
Twitter logo
10 Dec, 4 tweets, 2 min read
WELL I'm going to have to dig into this. Reminder that vaccine development is not straightforward, despite the super-exciting day we are having watching #VRBPAC

Australian COVID vaccine terminated due to HIV ‘false positives’ smh.com.au/politics/feder…
"The UQ vaccine candidate uses a protein and adjuvant platform, containing the COVID-19 spike protein and a "molecular clamp". A small component is derived from.... HIV, that is not able to infect people or replicate."

Any details out there?
precisionvaccinations.com/vaccines/uq-cs…
So @sesiegler pointed me to an example from the CAR T-cell world where a false-positive HIV nucleic acid test occurred

pubmed.ncbi.nlm.nih.gov/28610774/

• • •

Missing some Tweet in this thread? You can try to force a refresh
　

Keep Current with Matt Hall

Matt Hall Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @cispt2

Matt Hall Profile picture
11 Dec
So here's an update on the abandoned UQ COVID vaccine named UQ-CSL v451

uq.edu.au/news/node/1279…
First, the release states that the vaccine worked: vaccine elicited a response and "There were no serious adverse events or safety concerns reported in the 216 trial participants"
BUT the vaccine trials will not advance to Phase 2/3, according to @CSL
Read 24 tweets
Matt Hall Profile picture
9 Dec
Our @NIHDirector says @ncats_nih_gov have been "everywhere you look" on COVID-19 science !!

Part of a @MilkenInstitute Conversation with Dr. Francis Collins, Director, @nih (and Michael Milken)

vimeo.com/486353483
There were three examples that @NIHDirector gave.

First, tackling a battery of assays, screening of all libraries for SARS-COV-2, and sharing data openly through our OpenData Portal

opendata.ncats.nih.gov/covid19
Second, N3C "the boldest effort to get everyone to contribute clinical data so we can learn what is happening with patients affected with COVID19"

ncats.nih.gov/n3c
Read 7 tweets
Matt Hall Profile picture
13 Sep
Well - huge issues here. Not sure this article will be around for long.

And it's just samples collected for a completely different study (on asthma), and they checked TMPRSS2.

"Race" isn't mentioned in the awarded R01 - it's an asthma grant from NIAID.
grantome.com/grant/NIH/R01-…
I have a terrible feeling that ran TMPRSS2 expression on their samples, looked for a differential based on what they know about study sample donors (rather than having a hypothesis), and were like "welp, 'race' is a thing with COVID let's go with that".
I mean, there are enough studies showing this approach is not valid:

"These results suggest that .... careful consideration of self-identified race in gene expression profiling studies is needed to avoid spurious association."

ncbi.nlm.nih.gov/pmc/articles/P…
Read 4 tweets
Matt Hall Profile picture
5 Apr
OK so let's talk about camostat, because I'm starting to worry about it as a #COVID19 repurposing candidate. It emerged based on this Cell paper, but a LOT of assumptions are buried in the science.
cell.com/cell/fulltext/… Image
That Cell paper calls camostat "calls camostat “a clinically proven inhibitor of the cellular serine protease TMPRSS2” – which is not strictly correct.

It’s a clinically used drug (in Japan)

It has been shown to act on TMPRSS2 indirectly

Separate points. @Dereklowe
So what is camostat used for?

It's a serine protease inhibitor, and in Japan it's approved for treating pancreatitis. In that indiciation, doses are 600 mg are given. Data indicates it acts via anti-inflammatory action:
nature.com/articles/37002…
Read 14 tweets
Matt Hall Profile picture
30 Jan 19
This article on a 'miracle cure' for cancer has me so angry. How can unpublished, non-peer reviewed tripe get any attention at all? Some of the issues are in the thread below:
jpost.com/HEALTH-SCIENCE…
First, the experimental theraputic modality is based on phage-display-derived peptides against various targets that are apparently coupled together with a 'peptide toxin'. Presumably the peptide toxin is Monomethyl auristatin E
Next, the article states they have "concluded its first exploratory mice experiment, which inhibited human cancer cell growth and had no effect at all on healthy mice cells".
Read 11 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!

Like this author's thread?

Get emails when @cispt2 has new unrolls!

Check out other threads from @cispt2!

Read all threads by @cispt2